Private Market View

Nuvalent

Drug Discovery

Last price · $/share
Implied valuation
Total raised
$135.0M
Last round
Early Stage VC (Series B)
May 2021

Key facts

  • It has raised $135.0M across 1 recorded rounds; the latest was Early Stage VC (Series B) ($135.0M) in May 2021.
  • 6 institutional filers report fund marks on Nuvalent across 60 filings.
  • Nuvalent has filed 1 Form D with the SEC, most recently May 2021 ($135.0M sold to 28 investors).
Free account
See the evidence behind this price
  • ·Post-money valuations for all 1 rounds
  • ·Watchlist + deal alerts for Nuvalent
Create free account
No card required

Funding rounds

1 rounds
May 2021Early Stage VC (Series B)$135.0M

About Nuvalent

Industry
Drug Discovery
PA Mark — not yet priced

Nuvalent doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in Nuvalent shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

6 filers · latest May 2026

6 SEC-registered funds reported 60 fair-value marks on Nuvalent between Apr 2025 and May 2026. Filer-level marks and implied $/share are available to Pro members.